Pharmaceuticals
SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector
ZUG, Switerland, May 11, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inf...
2023-05-11 09:00
6185
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
ROCKVILLIE, Md. and SUZHOU, China, May 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-11 08:45
6336
Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
* Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapyin Europe * IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer PARIS, May 10, 2023 /PRNewswire/ -- Servier, a global pharmaceutical group...
2023-05-10 20:58
2510
Doceree forms an exclusive partnership with Hello Health Group to strengthen its global footprint; forays into 8 South East Asian markets
The partnership opens a first-of-its-kind service for Hello Health Group's
pharmaceutical clients,enabling them to target HCPs with precision and
efficiency
NEW DELHI, May 10, 2023 /PRNewswire/ -- Doceree
2023-05-10 11:00
5457
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ...
2023-05-10 08:00
6798
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
FLORENCE, Italy and NEW YORK, May 9, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to ...
2023-05-09 22:57
6385
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
* This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID * Preliminary topline immune responses for all three vaccine candidates were robust versus authorized comparators * For the stand-alone influenza vaccine candid...
2023-05-09 18:28
4753
Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases
* HMBD-011 is a potentially first-in-class anti-VH4-34 antibody developed for treatment of VH4-34+ antibody-driven pathogenesis in lupus and cold agglutinin disease * Data presented shows preclinical proof of concept for HMBD-011 clearance of VH4-34+ antibodies and effective inhibition of col...
2023-05-08 18:30
2784
Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed that ...
2023-05-08 16:50
4225
Transcenta to Present Two Clinical Trial Progress at ASCO 2023
SUZHOU, China, May 8, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that two posters for c...
2023-05-08 14:55
3622
EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
TAIPEI, May 8, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A inEurope. Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show th...
2023-05-08 10:00
3617
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-08 08:00
5954
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-08 08:00
5416
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Pha...
2023-05-08 05:00
6551
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites
MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injectio...
2023-05-08 05:00
3855
Empowering Innovation to the Global Market with Acro Certify
TOKYO, May 6, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. It is an immense logistical and financial challenge that makes or breaks a company, despite the product itself. For companies in that awkward, transitional stage from start-up company to a m...
2023-05-06 10:18
5629
Viva Biotech's Recent Conferences & Events Review
HONG KONG, May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Fu...
2023-05-05 19:58
5079
P&G Health commemorates Neuropathy Awareness Week 2023 with an effort to help people 'Put Life Back in Their Hands'
* Dons the purple ribbon for the 2nd consecutive year to raise awareness on Peripheral Neuropathy, a condition significantly underdiagnosed and undertreated inAsia, Middle East & Africa * Releases new research study highlighting the role of B Vitamins in supporting healthy nerve functions SIN...
2023-05-05 11:30
5284
SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology
* SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistantE. coli, which can cause fatal infections in vulnerable hematological cancer patients * SNIPR001 represents the first CRISPR- therapeutic developed to specifically removeE. coli in the ...
2023-05-05 00:52
3207
ANGUS ANNOUNCES CORPORATE REBRANDING, WILL CHANGE NAME TO "ADVANCION"
New name and brand reflect Company's strategic transformation into a leading global producer of specialty ingredients for Life Sciences, Personal Care and other essential markets BUFFALO GROVE, Ill., May 4, 2023 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company") today unveiled a new n...
2023-05-04 21:00
5227
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 292 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 281 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 279 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Amap and Sands China mark the delivery of the first Tutu robots, with expected indoor navigation and 3D resort previews
2026-10-10 16:43
16726
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
16655
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
14362
Zoomlion Expands Mining Machinery Business as International Revenue Grows
2026-10-10 16:58
8354
